Colorectal Cancer
Scope & Guideline
Exploring Breakthroughs in Colorectal Cancer Care
Introduction
Aims and Scopes
- Clinical Management of Colorectal Cancer:
The journal publishes studies that explore various treatment modalities, including chemotherapy, immunotherapy, and novel drug applications, emphasizing their effectiveness and impact on patient outcomes. - Molecular and Genetic Insights:
Research focusing on the molecular and genetic underpinnings of colorectal cancer is a key area, highlighting the identification of biomarkers and genetic subtypes that can influence prognosis and treatment responses. - Health Economics and Cost-Effectiveness:
A unique contribution of the journal is its exploration of the economic aspects of colorectal cancer treatment, evaluating the cost-effectiveness of different therapeutic approaches and their implications for healthcare systems. - Epidemiology and Public Health:
The journal addresses the epidemiological trends in colorectal cancer, including incidence and mortality rates, with a focus on demographic variations and public health strategies. - Patient-Centric Outcomes:
Research on the quality of life and psychosocial factors affecting patients with colorectal cancer is emphasized, ensuring that treatment approaches consider the holistic well-being of patients.
Trending and Emerging
- Immunotherapy and Tumor Microenvironment:
There is a notable trend towards understanding the tumor immune microenvironment and its role in response to immunotherapy, emphasizing the importance of immune-related factors in treatment efficacy. - Socio-Demographic Factors in Treatment Outcomes:
Recent studies highlight the impact of socio-demographic factors, such as geographical location and biological sex, on treatment delays and outcomes, indicating a shift towards more personalized and context-aware approaches. - Molecular Subtyping and Personalized Medicine:
The identification of molecular subtypes of colorectal cancer is gaining traction, reflecting a broader movement towards personalized medicine that tailors treatment based on genetic and molecular profiles. - Quality of Life Metrics in Treatment Evaluation:
An increasing focus on patient-reported outcomes and quality of life measures is evident, with researchers emphasizing the importance of these factors in evaluating treatment success.
Declining or Waning
- Traditional Chemotherapy Protocols:
Research centered on conventional chemotherapy protocols appears to be waning, as newer treatment modalities and personalized medicine take precedence in the literature. - Basic Science Studies without Clinical Relevance:
There seems to be a reduction in basic science studies that do not directly translate into clinical implications, reflecting a growing preference for research that can inform treatment and patient care. - Historical Epidemiological Studies:
While epidemiology remains important, studies focusing solely on historical data without contemporary relevance or actionable insights are becoming less frequent.
Similar Journals
BREAST CANCER RESEARCH AND TREATMENT
Uncovering Breakthroughs in Breast Cancer TreatmentBreast Cancer Research and Treatment, published by Springer, stands as a pivotal journal within the domains of Cancer Research and Oncology, exemplified by its impressive Q2 and Q1 quartile rankings, respectively, in the 2023 category rankings. Since its inception in 1981, this journal has provided a vital platform for disseminating cutting-edge research focused on all aspects of breast cancer, ranging from molecular biology to treatment strategies. With an ISSN of 0167-6806 and E-ISSN of 1573-7217, it captures a broad audience of researchers, clinicians, and students dedicated to improving patient outcomes. The journal emphasizes high-quality, peer-reviewed studies that pave the way for advancements in therapy and direct novel insights into oncological practices. By maintaining a strong ranking in Scopus with percentile placements of 74th in Oncology and 61st in Cancer Research, Brest Cancer Research and Treatment continues to foster innovation and collaboration in the fight against breast cancer.
Gastric Cancer
Shaping the Future of Gastric Cancer Care.Gastric Cancer is a leading journal in the field of oncology, published by SPRINGER in Japan. With an ISSN of 1436-3291 and an E-ISSN of 1436-3305, this esteemed journal aims to disseminate high-quality research focused on all aspects of gastric cancer, including its pathophysiology, diagnosis, treatment, and prevention. As an indicator of its academic excellence, Gastric Cancer is ranked in the top quartile (Q1) for Cancer Research, Gastroenterology, Medicine (miscellaneous), and Oncology categories as of 2023. The journal holds impressive Scopus rankings, being positioned #9 in Gastroenterology and #34 in Oncology, demonstrating its critical role in shaping advancements within these disciplines. Although not an open-access publication, it provides various access options for institutions and individuals looking to elevate their understanding of gastric cancer. With a converged publication history from 2000 to 2024, it serves as a vital resource for researchers, professionals, and students dedicated to eradicating this formidable disease.
Therapeutic Advances in Gastroenterology
Pioneering research in gastrointestinal therapy.Therapeutic Advances in Gastroenterology, published by SAGE Publications Ltd, is a premier open access journal dedicated to the advancement of knowledge in the field of gastroenterology. Since its inception in 2008 and its transition to open access in 2018, the journal has consistently provided high-quality peer-reviewed research articles, review papers, and clinical studies that address the latest therapeutic advancements and challenges in gastrointestinal medicine. With an impressive impact factor and a 2023 Scopus ranking placing it in the Q1 quartile of gastroenterology journals, it stands as a leading platform for researchers, clinicians, and healthcare professionals. The journal’s commitment to disseminating impactful research has positioned it at the forefront of academic discourse, offering a vital resource for those devoted to improving patient outcomes in digestive health. The United Kingdom-based journal invites submissions that contribute to the understanding and treatment of gastrointestinal disorders, ensuring that cutting-edge findings reach a global audience.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Pioneering Insights in Cancer Treatment and Research.JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.
European Urology Oncology
Delivering high-quality, peer-reviewed content for medical excellence.European Urology Oncology is a premier academic journal dedicated to advancing the field of urological oncology through innovative research and interdisciplinary collaboration. Published by Elsevier and based in the Netherlands, this journal runs on the principles of providing high-quality, peer-reviewed content that meets the evolving needs of professionals in medicine, surgery, and oncology. With an impressive 2023 categorization in the Q1 quartiles across multiple disciplines including Medicine (Miscellaneous), Oncology, and Urology, the journal demonstrates its pivotal role in disseminating essential findings that enhance clinical practices. The E-ISSN of this journal is 2588-9311, ensuring accessibility to groundbreaking articles that influence treatment methodologies and patient outcomes. Researchers and professionals relying on the latest evidence in urology and oncology will find this journal essential for keeping abreast of cutting-edge developments and clinical insights that shape the future of healthcare.
Tumori Journal
Transforming Cancer Research into Clinical Practice.Tumori Journal is a distinguished publication in the field of oncology, dedicated to advancing the understanding and treatment of cancer since its inception in 1946. Published by SAGE Publications Ltd, this Italian journal serves as a pivotal platform for researchers, clinicians, and academicians to disseminate cutting-edge findings in cancer research and related areas of medicine. With an impressive record of contributions spanning multiple decades, Tumori Journal aims to foster collaboration and dialogue among professionals in the oncology community. Although classified in the Q4 category for Cancer Research and the Q3 category for both Medicine (miscellaneous) and Oncology as of 2023, the journal continues to draw interest with its rigorous peer-review process and commitment to quality. Researchers are encouraged to explore innovative methodologies and share impactful clinical insights through the journal, which also ranks within the top tiers of Scopus metrics for oncology and cancer research domains. With a growing emphasis on accessible research, Tumori Journal remains an essential resource in the continuous fight against cancer.
Cancers
Advancing cancer research for a healthier tomorrow.Cancers is a leading peer-reviewed journal published by MDPI, dedicated to advancing the field of oncology and cancer research. Established in 2009 and based in Switzerland, this Open Access journal provides a platform for the rapid dissemination of high-quality research findings, reviews, and clinical studies related to all aspects of cancer biology and treatment. With an impressive impact factor and recognized as Q1 in Oncology and Q2 in Cancer Research for 2023, Cancers strives to foster a collaborative environment among researchers, healthcare professionals, and students seeking to deepen their knowledge and understanding of cancer. The journal’s commitment to accessibility and its broad scope make it an invaluable resource for anyone passionate about combating cancer and improving patient outcomes. For more information and to access its diverse publications, visit the journal’s website.
BMC CANCER
Connecting Researchers for a Cancer-Free FutureBMC CANCER is a prestigious, peer-reviewed journal dedicated to advancing the field of cancer research and oncology since its inception in 2001. Published by BMC, a leading name in open-access publishing, this journal plays a crucial role in providing researchers, professionals, and students with a platform for high-quality scientific discourse. With an impressive impact factor, BMC CANCER is ranked in the Q2 quartile across multiple categories, including Cancer Research, Genetics, and Oncology, reflecting its commitment to impactful research and rigorous peer-review standards. The journal ensures broad accessibility to its content through its Open Access model, allowing findings to reach a global audience without financial barriers. The editorial board consists of recognized experts committed to fostering innovation and collaboration within the cancer research community. Researchers working at the intersection of cancer biology, treatment options, and genetic influences will find BMC CANCER an invaluable resource for sharing their findings and engaging with the latest developments in the field.
Clinical Medicine Insights-Oncology
Bridging gaps in cancer treatment and management.Clinical Medicine Insights-Oncology is a leading journal published by SAGE Publications Ltd, focusing on the interdisciplinary aspects of oncology. With an open access model since 2007, this journal fosters the dissemination of high-quality research and clinical insights that are crucial for advancing knowledge in cancer treatment and management. Based in New Zealand, it aims to bridge gaps in current oncology practices through the publication of innovative studies, case reports, and reviews. With a respectable ranking in Scopus at #264 out of 404 journals in the oncology category and belonging to the Q3 quartile, it positions itself as a valuable resource for oncologists, researchers, and students committed to enhancing patient outcomes. This journal strives to provide a platform for groundbreaking research that can impact clinical practice and inform policy within the field of oncology.
Journal of Thoracic Oncology
Advancing the Frontiers of Thoracic Cancer ResearchJournal of Thoracic Oncology, published by Elsevier Science Inc, is a premier scholarly outlet dedicated to advancing the field of thoracic oncology. With an impressive impact factor and consistently rated in the Q1 quartile across several pertinent categories such as Medicine, Oncology, and Pulmonary and Respiratory Medicine, this journal stands at the forefront of research dissemination. Covering a broad scope that includes innovative therapeutic approaches, clinical trials, and the molecular underpinnings of thoracic malignancies, the journal serves as a vital resource for researchers, healthcare professionals, and students seeking to enhance their understanding of thoracic cancer and its treatment. With publication dates converging from 2006 to 2024, the Journal of Thoracic Oncology fosters a collaborative scholarly community by providing a platform for high-quality research while ensuring accessibility through traditional publication formats. Positioned in the heart of New York City, this journal not only reflects the cutting-edge advancements in oncology but also plays a pivotal role in shaping the future of thoracic cancer care.